

Supplemental table S1. Characteristics of the study population according to levels of metabolic control in the 24 months after diagnosis of T2D.

VARIABLE	Total	HbA1c <5.7%	HbA1c 5.7-6.4%	HbA1c 6.5-7.0%	HbA1c 7.1-8.0%	HbA1c >8.0%	p-value
No. of patients	237635	12712 (5.3)	72986 (30.7)	61429 (25.9)	58305 (24.5)	32203 (13.6)	
Age at baseline (years)	64.2±12.3	61.0±13.0	64.3±11.7	65.3±11.7	64.8±12.5	62.3±13.5	<0.0001
Gender (% males)	56.6	63.8	57.1	54.2	56.2	57.9	<0.0001
BMI (kg/m ²)	29.9±5.6	29.1±5.3	29.6±5.4	29.9±5.5	30.1±5.7	30.5±6.1	<0.0001
Smoking (%)	20.0	16.1	17.8	19.1	21.6	25.2	<0.0001
HbA1c at baseline (%)	6.8±1.1	5.4±0.4	6.1±0.4	6.6±0.4	7.1±0.7	8.4±1.7	<0.0001
HbA1c at diagnosis (%)	8.3±2.3	7.5±2.3	7.6±2.0	8.0±2.0	8.8±2.2	9.9±2.4	<0.0001
Total cholesterol (mg/dl)	184.5±39.5	180.6±37.7	184.1±38.3	184.5±38.8	183.7±39.7	188.3±43.3	<0.0001
HDL cholesterol (mg/dl)	49.5±13.3	50.3±13.9	50.8±13.4	50.0±13.2	48.5±13.1	46.8±13.1	<0.0001
LDL cholesterol (mg/dl)	107.4±34.0	105.6±32.6	107.6±33.3	107.3±33.7	106.5±34.3	109.5±36.3	<0.0001
Triglycerides (mg/dl)	143.0±87.6	126.3±77.0	132.5±76.7	141.0±80.2	148.6±88.7	167.4±116.4	<0.0001
Systolic blood pressure (mmHg)	134.1±17.9	132.0±17.9	133.4±17.6	134.4±17.6	134.9±18.1	134.9±18.8	<0.0001
Diastolic blood pressure (mmHg)	78.8±9.9	78.1±9.8	78.5±9.6	78.8±9.7	79.1±10.0	79.6±10.4	<0.0001
Albuminuria (%)	35.6	30.9	32.5	34.0	37.9	43.4	<0.0001
eGFR <60 ml/min/1.73m ² (%)	19.8	16.5	18.6	20.2	21.4	20.5	<0.0001
Antihypertensive medication (%)	51.9	48.0	53.0	54.2	52.2	46.3	<0.0001
Lipid-lowering medication (%)	40.7	31.6	40.9	43.8	41.9	36.1	<0.0001
Glucose-lowering medication (%)							
Metformin	62.5	49.9	53.2	62.0	72.6	71.5	<0.0001
Sulphonylureas	11.4	5.9	5.9	8.2	15.8	24.0	<0.0001
Glinides	3.8	2.3	2.4	3.1	5.1	6.4	<0.0001
DPP4i	9.9	4.6	5.2	7.8	16.1	15.5	<0.0001
GLP1-RAs	2.8	1.6	1.4	2.0	4.1	5.8	<0.0001
SGLT2i	3.6	1.4	1.8	2.9	5.2	6.9	<0.0001
Thiazolidinediones	2.7	1.4	1.6	2.2	3.9	4.3	<0.0001
Acarbose	1.9	0.9	1.2	1.7	2.7	2.7	<0.0001
Insulin	18.0	13.8	9.5	10.8	22.0	45.7	<0.0001
Follow-up (years)	4.5±2.7	4.5±2.7	4.5±2.7	4.5±2.7	4.4±2.7	4.4±2.7	<0.0001
Composite CV Outcome	5.4	3.5	4.9	5.6	6.1	6.0	<0.0001
HbA1c measurements during exposure period	3.8±1.8	3.3±1.7	3.6±1.7	3.7±1.8	4.1±1.9	4.0±2.1	<0.0001

Supplemental table S2. Characteristics of the study population according to levels of metabolic control in the 36 months after diagnosis of T2D.

VARIABLE	Total	HbA1c <5.7%	HbA1c 5.7-6.4%	HbA1c 6.5-7.0%	HbA1c 7.1-8.0%	HbA1c >8.0%	p-value
No. of patients	210385	4.9	64265 (30.5)	55468 (26.4)	53934 (25.6)	26428 (12.6)	
Age at baseline (year)	64.8±12.2	61.6±13.1	65.0±11.6	65.9±11.6	65.3±12.3	62.5±13.4	<0.0001
Gender (% males)	56.4	63.4	56.7	54.3	56.3	57.9	<0.0001
BMI (kg/m ²)	30.0±5.6	29.2±5.4	29.6±5.4	30.0±5.4	30.2±5.7	30.7±6.1	<0.0001
Smoking (%)	19.8	16.0	17.6	19.1	21.5	25.5	<0.0001
HbA1c at baseline (%)	6.8±1.1	5.4±0.4	6.1±0.4	6.7±0.5	7.2±0.8	8.5±1.7	<0.0001
HbA1c at diagnosis (%)	8.2±2.2	7.4±2.3	7.6±2.0	7.9±2.0	8.7±2.2	9.7±2.4	<0.0001
Total cholesterol (mg/dl)	182.4±39.0	179.8±37.2	182.3±37.7	182.1±38.3	181.0±39.2	187.0±43.1	<0.0001
HDL cholesterol (mg/dl)	49.5±13.4	50.7±14.3	51.0±13.5	49.9±13.1	48.3±13.0	46.6±13.1	<0.0001
LDL cholesterol (mg/dl)	105.3±33.7	104.5±32.4	105.6±32.8	105.0±33.3	103.9±33.8	108.2±36.5	<0.0001
Triglycerides (mg/dl)	143.1±86.8	126.6±76.7	132.0±74.1	140.6±79.2	149.4±89.5	169.1±117.1	<0.0001
Systolic blood pressure (mmHg)	134.4±17.8	131.9±17.5	133.6±17.5	134.4±17.6	135.2±18.1	135.2±18.7	<0.0001
Diastolic blood pressure (mmHg)	78.8±9.7	78.0±9.6	78.4±9.5	78.7±9.6	79.0±9.8	79.7±10.3	<0.0001
Albuminuria (%)	39.4	33.6	36.1	38.0	41.8	48.0	<0.0001
eGFR <60 ml/min/1.73m ² (%)	21.6	18.1	20.4	21.8	23.1	22.5	<0.0001
Antihypertensive medication (%)	55.0	50.1	55.8	57.4	55.5	48.8	<0.0001
Lipid-lowering medication (%)	45.1	34.8	44.9	48.2	46.9	39.5	<0.0001
Glucose-lowering medication (%)							
Metformin	65.3	49.3	55.3	66.1	75.7	73.1	<0.0001
Sulphonylureas	13.2	5.7	6.2	9.3	19.3	28.7	<0.0001
Glinides	4.4	2.2	2.8	3.6	6.1	7.5	<0.0001
DPP4i	11.9	4.5	5.7	9.5	19.9	18.4	<0.0001
GLP1-RAs	3.5	1.4	1.5	2.4	5.6	7.2	<0.0001
SGLT2i	3.9	1.1	1.7	3.1	5.9	8.0	<0.0001
Thiazolidinediones	3.3	1.4	1.9	2.7	4.9	5.5	<0.0001
Acarbose	2.3	1.1	1.4	2.1	3.2	3.4	<0.0001
Insulin	18.6	13.0	9.1	11.2	23.6	49.3	<0.0001
Follow-up (years)	4.3±2.5	4.3±2.5	4.3±2.4	4.3±2.4	4.2±2.4	4.3±2.5	<0.0001
Composite CV Outcome	5.3	3.3	4.6	5.4	6.0	6.1	<0.0001
HbA1c measurements during exposure period	5.0±2.6	4.3±2.3	4.7±2.4	4.9±2.5	5.5±2.6	5.2±3.0	<0.0001